ANI PHARMACEUTICALS, INC Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory
ANI PHARMACEUTICALS, INC (ANIP) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory of $2.20 million as of 2018-08-06, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory · last filed 2018-11-06
- 2018-08-06: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory $2.20M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory |
|---|---|
| 2018-08-06 | $2.20M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |